J&J & 15 Pharma Companies Join Trump’s Drug Pricing Push
Johnson & Johnson announced a voluntary agreement with the Trump Administration on drug pricing aimed at improving access to medicines adn lowering costs for millions of American patients.1 The agreement, which meets President TrumpS requests to the pharmaceutical industry, also provides the company’s products with an exemption from tariffs.
“Today’s agreement is a win for American patients,” said Alex Azar, Secretary of Health and Human Services.”It demonstrates Johnson & Johnson’s commitment to working with the Administration to lower drug prices and increase access to life-saving medicines.”
Under the agreement, Johnson & Johnson will:
* Limit price increases on its products to no more than once per year and will not exceed inflation.
* Roll back previously announced price increases.
* Expand access to patient assistance programs.
in return, the Administration will exempt Johnson & Johnson’s products from potential tariffs.
“We are pleased to reach this agreement with the Trump administration,” said Alex Gorsky, Chairman and Chief Executive Officer of Johnson & Johnson.”We beleive this is a positive step forward that will help ensure patients have access to the medicines they need at affordable prices.”
The agreement is effective immediately and will remain in effect until January 1, 2025.
1 *Source: U.S. Department of Health and Human Services*
Johnson & Johnson has reached an agreement with the Trump administration to participate in TrumpRx.gov and offer discounted medicines to Americans, becoming the 15th of 17 companies contacted by the administration to sign on.
With Johnson & Johnson’s participation, 15 of 17 companies contacted by the administration over the summer have now signed on. Earlier deals had been announced with Pfizer, AstraZeneca, EMD Serono, Eli Lilly, and novo Nordisk.
As part of the agreement, Johnson & Johnson will participate in TrumpRx.gov, a direct-to-patient platform enabling Americans to purchase the company’s medicines at discounted rates.1
Drug Pricing and direct-to-Consumer Access
Table of Contents
The new agreements have a 2-track structure: first, the participating manufacturers will sell most of their drugs to Medicaid at prices comparable to those in European markets, where governments typically negotiate far more aggressively than the United States.2 Although Medicaid already receives the lowest domestic price available by law, officials have said that the new commitments could generate additional savings, notably for drugs that historically cost more in the United States despite global parity elsewhere.
Second, the companies will create online storefronts that allow Americans to purchase certain medications directly, bypassing insurers. The Trump administration plans to launch TrumpRx.gov as a centralized portal that guides consumers to company-specific sites.
in return for participating, companies will receive 3-year exemptions from any tariffs on imported pharmaceuticals that Trump may impose. The president has repeatedly threatened such tariffs as leverage, but has not enacted them. According to The New York Times, avoiding those penalties has been a strong incentive, as has avoiding the possibility of strict regulation.3
The administration’s push for voluntary deals has unfolded alongside work on potential drug-pricing regulations. Last year, officials went through the procedural steps for new rules, including proposals related to Medicare drug spending and global price benchmarking. Notices showing the completion of key regulatory reviews were posted online last month, though no final rules have been unveiled.
Johnson & Johnson Invests in Therapeutic Access
In addition to improving access
Trump Administration Secures Nine New Drug Pricing Agreements
The Trump administration brokered nine new agreements with pharmaceutical companies aimed at lowering drug prices, as manufacturers grapple with ongoing tariff pressures and evolving regulatory landscapes. The deals, announced December 19, 2025, build on previous efforts to negotiate lower costs for prescription medications.
Details of the Agreements
These agreements represent a continuation of the trump administration’s focus on drug pricing reform. While specific details of each agreement vary, they generally involve commitments from drugmakers to limit price increases or offer discounts on certain medications. The agreements are intended to address concerns about the high cost of prescription drugs, a key issue for American voters. According to a report by AJMC®, the agreements are a response to both tariff impacts and increased regulatory scrutiny.
Context: Tariff and Regulatory Pressures
Pharmaceutical companies have faced increasing pressure from multiple sources in recent years. Tariffs imposed on imported pharmaceutical ingredients have raised production costs, while proposed regulations aimed at increasing price transparency and competition have created uncertainty in the market. These factors have prompted drugmakers to seek ways to mitigate financial risks and maintain profitability. the agreements with the Trump administration offer a potential pathway to navigate these challenges.
Impact and Previous Efforts
The nine new agreements follow a series of similar deals struck earlier in the Trump administration. In 2024, several major pharmaceutical companies pledged to voluntarily cap price increases on certain drugs. The effectiveness of these earlier agreements has been debated, with some critics arguing that the price reductions have been limited.However, the administration maintains that these efforts have saved consumers money and spurred further negotiations. According to a statement released by the White House on December 20, 2025, the previous agreements resulted in an estimated $100 million in savings for patients.
Source
Trump strikes 9 new pricing agreements as drugmakers navigate tariff, regulatory pressure. AJMC®. December 19, 2025. accessed January 9, 2026.